Pfizer + Wyeth: What a difference another year can make.
Kindler has made it clear that there will be no big mergers, so he’s essentially asking everyone to continue to be patient until his many small moves—the cost cutting, the biotech acquisitions, the restructuring—show results. But patience is wearing thin. But Kindler can’t exactly go down to the lab and cook up some great new drugs all by himself.
PharmExec, March 2008
The message I hear is, 'Don't expect anything radical,' but the challenges require radical change," Morgan Stanley's Jami Rubin told the Wall Street Journal.
FiercePharma, March 2008
CEO Jeff Kindler says the drug giant is open to acquisitions large and small, so let the deal-making guessing game begin.
TheStreet, Jan 2009